- Press Releases
Ambry Genetics Publishes 43,000 Patient Study Showing Combined RNA and DNA Analysis Identifies Patients Who Are High-Risk for Cancer but Would Have Been Missed by DNA Testing Alone
Ambry Genetics, a leader in clinical diagnostic testing and a subsidiary of REALM IDx, Inc., announced today the findings of a study that showed paired RNA and DNA genetic testing, conducted at the same time, detected elusive pathogenic variants in 1 of every 950 patients that were missed by DNA testing alone.
August 30, 2022Read More
Cell Stress and Mitochondrial Dysfunction Found in Early Alzheimer’s Disease Patients, Findings Published in Science Translational Medicine
Invicro LLC (Invicro), a global, industry-leading imaging CRO, and a subsidiary of REALM IDx, Inc., today announced the publication of the paper “Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease” in Science Translational Medicine.
August 18, 2022Read More
SOPHiA GENETICS (Nasdaq: SOPH) and REALM IDx announced today that they signed a letter of intent to collaborate in the co-development of novel genomic applications and commercialization of multi-modal applications.
March 24, 2022Read More
REALM IDx, Inc., a leader in integrated diagnostics, announced the company will participate in the upcoming 40th Annual J.P. Morgan Health Care Conference. This premier health care conference features global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.
January 6, 2022Read More
"We're excited to announce the name change," said Dr. Aaron Elliott, Chief Executive Officer of REALM IDx, Inc. "Our new name reflects not only our focus on advancing integrated diagnostics, but also the coming together of the rich multi-modal data generated by our subsidiary companies – genomics from Ambry Genetics, and radiology and pathology from Invicro.
September 15, 2021Read More
PRECEDE Consortium Announces Konica Minolta Precision Medicine as its Precision Health Partner to Advance its Mission to Increase Survival Rates for Patients with Pancreatic Cancer
Together, KMPM and PRECEDE Consortium will bring their expertise and resources in genetic testing, pathology, and imaging to determine who is at an elevated risk for developing pancreatic cancer, define that risk, and invite those at elevated risk into state-of-the art clinical screening programs.
August 17, 2021Read More
Konica Minolta Precision Medicine collaborates with AWS to Create the Next Generation of Precision Diagnostics
Konica Minolta Precision Medicine, Inc. (KMPM) announced today a five-year collaboration with Amazon Web Services, Inc. (AWS). As the Preferred Cloud Provider for KMPM, AWS will support the build-out of the company's LATTICE™ initiative globally.